Join our daily newsletter At The Bell to receive exclusive market insights
- Medical Developments International (MVP) has announced positive results from multiple studies completed using its pain-reducing drug
- The self-administered drug is commonly used by patients who are undergoing procedures and has already received sales of more than 5 million
- Tests have shown the drug to have superiority over already existing treatments
- MVP’s share price is up 12 per cent, with shares trading for $5.79 apiece
Medical Developments International (MVP) has announced positive results from testing Penthrox.
Penthrox is a fast onset, non-opioid analgesic that is indicated for pain relief by self-administration in patients who require pain killers for surgical procedures.
The product has been used for more than 40 years in Australia and more than five million units of it have been sold.
There is a growing interest in Penthrox being used in patients who are undergoing investigatory procedures and operational procedures such as a colonoscopy.
This most recent study demonstrated that Penthrox has superiority over intravenous (directly into a vein) morphine, paracetamol, ketoprofen, and non-steroidal anti-inflammatory drugs (NSAIDS) within a trauma setting.
When added to a standard of care, Penthrox shows dominance over placebo in a trauma setting.
Penthrox was shown to be successful in dislocation injuries and resulted in less time spent in emergency departments thus improving patient experience and reducing crowding.
Other studies confirmed that Penthrox is effective, well tolerated and rapidly acting in trauma settings.
Studies completed show that Penthrox exceeded both patient and clinician expectations and resulted in a high degree of treatment satisfaction from patients and health care professionals.
While some people tolerated Penthrox, the most adverse event that was experienced was mild and temporary.
MVP CEO John Sharman is pleased with the results received from trials of Penthrox.
“We are delighted with the results of these recent European clinical trials demonstrating the superiority of Penthrox over standard of care treatments (intravenous, morphine, IV, paracetamol, ketoprofen or NSAIDS),” John said.
“This reinforces the global potential for Penthrox as a simple, fast and effective non-opioid pain medication,” he added.
Shares in MVP are up 12 per cent and trading for $5.79 a share in a $379.8 million market cap.
